SCHEMBL2302363

SCHEMBL2302363

CC(C)(C)NCN1CC(O)C1

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2298492 0.81 DPP4 (0.38) DPP4
SCHEMBL2298520 0.81 DPP4 (0.35) DPP4
SCHEMBL2297645 0.79 DPP4 (0.41) DPP4
SCHEMBL25043343 0.78 KDM4E (0.40) DPP4
SCHEMBL2299117 0.78
SCHEMBL2298751 0.75 ATM (0.34)
SCHEMBL2296486 0.74
SCHEMBL14433561 0.72 NPSR1 (0.39)
SCHEMBL2296528 0.71 SIGMAR1 (0.33) DPP4
SCHEMBL18159704 0.69 CACNA1H (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999006-B2 Anticancer agents; mitogen-activated protein kinases (MEK) EXELIXIS, INC. (US) 2011-08-16 US claimed